CN101505760A - 包含星形孢菌素类的组合 - Google Patents

包含星形孢菌素类的组合 Download PDF

Info

Publication number
CN101505760A
CN101505760A CNA200780030602XA CN200780030602A CN101505760A CN 101505760 A CN101505760 A CN 101505760A CN A200780030602X A CNA200780030602X A CN A200780030602XA CN 200780030602 A CN200780030602 A CN 200780030602A CN 101505760 A CN101505760 A CN 101505760A
Authority
CN
China
Prior art keywords
mcl
lower alkyl
typically
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780030602XA
Other languages
English (en)
Chinese (zh)
Inventor
P·瓦伦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101505760A publication Critical patent/CN101505760A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA200780030602XA 2006-06-23 2007-06-22 包含星形孢菌素类的组合 Pending CN101505760A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612542.1A GB0612542D0 (en) 2006-06-23 2006-06-23 Combinations comprising staurosporines
GB0612542.1 2006-06-23

Publications (1)

Publication Number Publication Date
CN101505760A true CN101505760A (zh) 2009-08-12

Family

ID=36803826

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780030602XA Pending CN101505760A (zh) 2006-06-23 2007-06-22 包含星形孢菌素类的组合

Country Status (12)

Country Link
US (1) US20100184820A1 (https=)
EP (1) EP2037933A2 (https=)
JP (1) JP2009541240A (https=)
KR (1) KR20090033874A (https=)
CN (1) CN101505760A (https=)
AU (1) AU2007263278A1 (https=)
BR (1) BRPI0713730A2 (https=)
CA (1) CA2655724A1 (https=)
GB (1) GB0612542D0 (https=)
MX (1) MX2008016488A (https=)
RU (1) RU2009101972A (https=)
WO (1) WO2007147613A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083830A (zh) * 2016-06-01 2016-11-09 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106146475A (zh) * 2016-06-01 2016-11-23 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN107569491A (zh) * 2017-08-30 2018-01-12 杭州科兴生物化工有限公司 一种星孢菌素类化合物的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143578A1 (en) * 2008-05-28 2009-12-03 The Council Of The Queensland Institute Of Medical Research Cancer drug target and methods of diagnosis and therapy
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
FI20115640A0 (fi) * 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
DK2872631T3 (en) * 2012-07-13 2017-06-12 Turun Yliopisto COMBINATION THERAPY
SG10201607303YA (en) 2016-09-01 2018-04-27 Agency Science Tech & Res Antisense oligonucleotides to induce exon skipping
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
CN114437109B (zh) * 2022-03-08 2023-09-29 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种十字孢碱卤代衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
ES2269793T3 (es) * 2001-10-30 2007-04-01 Novartis Ag Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
BRPI0413439A (pt) * 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083830A (zh) * 2016-06-01 2016-11-09 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106146475A (zh) * 2016-06-01 2016-11-23 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106146475B (zh) * 2016-06-01 2019-05-17 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN110218206A (zh) * 2016-06-01 2019-09-10 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN110218206B (zh) * 2016-06-01 2022-03-04 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN107569491A (zh) * 2017-08-30 2018-01-12 杭州科兴生物化工有限公司 一种星孢菌素类化合物的应用

Also Published As

Publication number Publication date
WO2007147613A3 (en) 2008-07-03
MX2008016488A (es) 2009-01-22
CA2655724A1 (en) 2007-12-27
JP2009541240A (ja) 2009-11-26
US20100184820A1 (en) 2010-07-22
EP2037933A2 (en) 2009-03-25
WO2007147613A2 (en) 2007-12-27
BRPI0713730A2 (pt) 2012-10-30
GB0612542D0 (en) 2006-08-02
AU2007263278A1 (en) 2007-12-27
KR20090033874A (ko) 2009-04-06
RU2009101972A (ru) 2010-07-27

Similar Documents

Publication Publication Date Title
CN101505760A (zh) 包含星形孢菌素类的组合
Donev et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer
CA2979530C (en) Inos-inhibitory compositions and their use as breast cancer therapeutics
CN113924365A (zh) 用于治疗kras相关疾病或病症的组合物和方法
US11179412B2 (en) Methods of treating conditions involving elevated inflammatory response
WO2025054270A1 (en) Compositions and methods for treating cancer
US20130195926A1 (en) Modulation of nitric oxide signaling to normalize tumor vasculature
US20240408091A1 (en) Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders
CN114761006A (zh) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP2010509258A (ja) アデノシンアンタゴニストの使用
JP2019512543A (ja) β−カテニン関連疾患又は障害の治療のための組成物及び方法
WO2013165320A1 (en) Treating cancer by increasing expression of socs6
WO2010026660A1 (ja) Ｚｆａｔ遺伝子発現抑制ｒｎａ
JP5406024B2 (ja) Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
PT2415870T (pt) Molécula de arni para timidilato sintase e utilização da mesma
WO2020239685A1 (en) Combinations of therapeutic agents for treating uveal melanoma
US20230123601A1 (en) Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
WO2025087879A2 (en) Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
WO2019107487A1 (ja) マイクロｒｎａ及びその誘導体を有効成分とする医薬組成物
WO2017160797A1 (en) Combination therapy with c-myc nucleic acid inhibitors and selective cdk7 inhibitors
WO2021237270A1 (en) Method of treating leukaemia
Borthakur et al. Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia
WO2023081927A2 (en) Treating chemoresistant forms of leukemia and other cancers that overexpress rna binding protein fxr1
EP4192956A2 (en) Human xist antisense oligonucleotides for x reactivation therapy
TW202440924A (zh) 抑制17β-羥基類固醇脫氫酶13型(HSD17B13)表達的組合物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090812